Le Lézard
Classified in: Health, Science and technology, Business

CB Therapeutics granted a new patent that will help further provide eco-conscious avenues for psychedelic research

CARLSBAD, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- CB Therapeutics (the "Company"), a biotechnology and precision fermentation company focused on using cellular agriculture to produce environmentally-friendly products for human health, has been granted a new patent covering the use of microorganisms to produce tryptamines and their analogs, such as psilocybin and various other molecules found in "magic" mushrooms. The patent marks yet another milestone for the Company in its journey to create safe, sustainable, and scalable compounds for various industries, researchers and clinicians.

This patent allows CB Therapeutics to own a production process that is the future of the psychedelic medicine industry. Almost all other methods to produce these molecules are costly, time-consuming or create significant amounts of toxic waste, CO2 and other byproducts that negatively impact the environment.

CB Therapeutics' cellular agriculture platform enables the conversion of cheap feedstocks into high-value compounds. The result is a scalable and eco-conscious supply chain, carried out by precision fermentation, which is the future for various products and therapeutics, including the psychedelic medicine industry.

"Businesses and research institutions in the emerging psychedelic industry need to get serious about ESG now because once the industry is established, it will be too late. Right now is the time to provide services that adhere to this paradigm change and we are motivated to grow as an innovative player in the industry. Our company may be small but we are doing big things to make the biotechnology sector more environmentally sustainable," says Sher Ali Butt, Co-Founder and CEO.

While patents tend to stir up controversy in regulated markets, they continue to be essential for small, innovative companies. They protect valuable IPs, which paves the way for smaller companies to work with large corporations, such as CB Therapeutics' recent partnership, launching TryptageniX with atai Life Sciences. Easing the way for such partnerships could help diversify service offerings in the psychedelic space through collaboration.

"Increasing access to safe and sustainably produced therapeutics is more achievable than ever before through innovations in synthetic biology and precision fermentation. We are very proud to be at the forefront of this movement, and to be a part of a growing number of groups innovating in the psychedelic medicine space to unlock these powerful molecules for researchers and clinicians to help patients with unmet needs," says Co-Founder, Jacob Vogan. "This is a ?rising tide lifts all boats' moment of societal benefit in accessing therapeutics through new sustainable processes."

The CB Therapeutics team of researchers, executives and esteemed advisory board members are hopeful this will better standardize eco-conscious research into products for human health, including foods, cannabinoids and psychedelic medicines. Furthermore, with ethical considerations applied, this patent gives rise to new molecules and therapies that will be faster and cheaper than currently available, ultimately benefiting the hundreds of millions of people who suffer from mental illnesses globally.

About CB Therapeutics

CB Therapeutics produces high-value molecules, compounds, and rare ingredients from simple sugars utilizing yeast and the process of fermentation. Since its inception, CB Therapeutics has developed standardized biotechnology processes for producing natural molecules and their analogs for clinical research in psychedelic medicine, cannabinoid-based therapies, and food technologies. As a drug discovery platform with the ability to create a clean and secure supply of products, The Company's partnership allows it to develop custom production process technologies to support and scale drug product manufacturing to meet clinical patient supply demands. In turn, this enables partners to move more swiftly through clinical development.

CB Therapeutics' expertise in synthetic genomics and bio-engineering has significantly advanced its proprietary production platform of microorganisms, enzymes, and production processes. After more than four years of research and development, the CB Therapeutics team can produce a broad range of phytochemicals faster, utilizing fewer resources, at greater yields, and with more purity, consistency, and efficiency than competing platforms. CB Therapeutics operates from their new 16,000 sq. ft. fully-licensed commercial batch facility in southern California.

Contact Information

Media Contact:
Alana Armstrong
Dir. of Communications, Alan Aldous Inc.
Email: [email protected]

Partnership Inquiries:
Sher Ali Butt
CEO, CB Therapeutics
Email: [email protected]

Follow CB Therapeutics on Twitter: @CBTherapeutics
Follow CB Therapeutics on Instagram: @cbthera


These press releases may also interest you

at 04:23
Biosyngen, a leading biotechnology company focused on the development of innovative cell therapies, recently announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China has approved the...

at 04:05
Azafaros B.V. today announced positive topline data from its RAINBOW study, a Phase 2 clinical trial investigating nizubaglustat in patients with a genetic diagnosis of either GM2 gangliosidosis or Niemann-Pick disease type C (NPC). About the Trial...

at 03:30
EQT Life Sciences is pleased to share that the LSP Dementia Fund...

at 03:05
CULT Food Science Corp. ("CULT" or the "Company") (FRA: LN00), a disruptive food technology platform pioneering the commercialization of lab grown meat and cellular agriculture to reshape the global food industry, congratulates venture arm company,...

at 03:00
Novo Holdings, a leading life science investor, today announces it led a...

at 03:00
Financing led by Novo Holdings, including new investment from EQT Life Sciences ? LSP Dementia Fund, OrbiMed and SR One with participation from existing investors M Ventures, Sofinnova Partners, GSK Equities Investments Limited and Johnson & Johnson...

News published on and distributed by: